Related Experiment Video

Updated: Mar 24, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation

Mikhail S Dzeshka1, Gregory Y H Lip2

  • 1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham B18 7QH, UK; Grodno State Medical University, Grodno, Belarus.

Heart Failure Clinics
|March 13, 2016
PubMed

Insights

Atrial fibrillation (AF) patients need antithrombotic prophylaxis to prevent stroke. Oral anticoagulation (OAC) is recommended over antiplatelet drugs, but individual stroke and bleeding risks must be assessed.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Atrial fibrillation (AF) significantly elevates stroke and thromboembolic event risk.
  • Antithrombotic prophylaxis is essential for most AF patients.
  • Oral anticoagulation (OAC) is a primary treatment strategy.

Purpose of the Study:

  • To review the role of antithrombotic prophylaxis in atrial fibrillation management.
  • To compare the efficacy and safety of different antithrombotic agents.

Main Methods:

  • Literature review of studies on antithrombotic therapies in AF.
  • Analysis of stroke and bleeding risk assessment tools.
  • Comparison of oral anticoagulants (VKAs and non-VKAs) with antiplatelet agents.

Main Results:

  • OAC, including vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs), is effective in preventing thromboembolic events in AF.
  • Risk assessment for stroke and bleeding is crucial for individualized treatment decisions.
  • Antiplatelet drugs are less effective than OAC for stroke prevention in AF and carry similar bleeding risks.

Conclusions:

  • OAC is the preferred antithrombotic strategy for AF patients at risk of stroke.
  • Individualized risk-benefit assessment is paramount in selecting antithrombotic therapy.
  • Antiplatelet therapy is not recommended as a substitute for OAC in AF.

Keywords:
Antiplatelet drugsAntithrombotic prophylaxisAtrial fibrillationBleeding riskOral anticoagulantsStroke risk

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
460
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
907
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
576